David Dalvey, Director, on May 04, 2026, sold 25,000 shares in Celcuity (CELC) for $3,517,000. Following the Form 4 filing with the SEC, Dalvey has control over a total of 65,000 common shares of the company, with 65,000 controlled indirectly.
SEC Filing:
John Anthony Maddison, Chief Product Marketing Officer, on May 01, 2026, sold 1,000 shares in F5 (FFIV) for $322,330. Following the Form 4 filing with the SEC, Maddison has control over a total of 2,149 common shares of the company, with 2,149 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1048695/000204605426000006/xslF345X05/wk-form4_1778017364.xml
Fady Ibraham Malik, Executive Vice President, Research & Development, on May 05, 2026, sold 3,500 shares in Cytokinetics (CYTK) for $270,795. Following the Form 4 filing with the SEC, Malik has control over a total of 153,902 common shares of the company, with 153,902 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1061983/000106198326000051/xslF345X05/form4.xml
Kunal Anand, Chief Technology Officer, on May 01, 2026, sold 3,123 shares in F5 (FFIV) for $1,006,637. Following the Form 4 filing with the SEC, Anand has control over a total of 12,194 common shares of the company, with 12,194 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1048695/000201685726000006/xslF345X05/wk-form4_1778017126.xml